Nouvelles stratégies thérapeutiques dans les cancers mammaire et tubo-ovarien de stade avancé [New therapeutic strategies in advanced stage breast and tubo-ovarian cancers]

Détails

ID Serval
serval:BIB_46BF62ED0C0E
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Nouvelles stratégies thérapeutiques dans les cancers mammaire et tubo-ovarien de stade avancé [New therapeutic strategies in advanced stage breast and tubo-ovarian cancers]
Périodique
Revue medicale suisse
Auteur(s)
Nikolopoulou A., Galli-Vareia I., Stravodimou A., Sarivalasis A., Zaman K.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Statut éditorial
Publié
Date de publication
15/05/2019
Peer-reviewed
Oui
Volume
15
Numéro
651
Pages
1027-1031
Langue
français
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
New targeted therapies modify therapeutic strategies for advanced stage breast and tubo-ovarian cancers. Chemotherapy and endocrine therapy remain the cornerstones of breast cancer treatment. Inhibitors of CDK4/6, mTOR and PI3K are associated with endocrine therapy to increase its effectiveness. PARP inhibitors outperform chemotherapy in BRCA1/2 mutation carriers. Immunotherapy integrates into the treatment of triple-negative cancers with very promising results. For tubo-ovarian cancers, the concept of « platinum-sensitive » has been tempered since the arrival of antiangiogenic treatment and PARP inhibitors that prolong the disease control not only in patients with BRCA1/2 mutation, but also in others.
Mots-clé
Antineoplastic Agents, Hormonal/therapeutic use, Breast Neoplasms/genetics, Breast Neoplasms/therapy, Female, Genes, BRCA1, Genes, BRCA2, Humans, Ovarian Neoplasms/genetics, Ovarian Neoplasms/therapy, Poly(ADP-ribose) Polymerase Inhibitors/therapeutic use
Pubmed
Création de la notice
03/06/2019 7:10
Dernière modification de la notice
20/09/2021 5:40
Données d'usage